{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:55:41Z","timestamp":1782496541058,"version":"3.54.5"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute Cancer Center","award":["P30CA196521"],"award-info":[{"award-number":["P30CA196521"]}]},{"name":"Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai"},{"name":"Biostatistics Shared Resource Facility"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor-T-cell (CAR-T) therapies are approved for refractory and relapsed multiple myeloma (MM). Patients with MM have high cardiovascular disease burden due to age and cardiotoxic treatments. Retrospective studies in patients who develop severe grades of cytokine release syndrome (CRS) demonstrated a 20\u201330% major cardiovascular adverse event (MACE) rate. Early use of an interleukin-6 receptor antagonist, tocilizumab, to reverse CRS may lower rates of MACE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This observational study sought to examine the relationship between early use of tocilizumab and the development of MACE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective chart review of adults undergoing CAR-T therapy for MM between 2017 and 2023 at a single medical center. Major cardiovascular adverse event was defined as a composite of myocardial injury, heart failure, stroke, arrhythmias, and cardiovascular death over a median period of 12 months. The secondary outcomes were progression-free survival (PFS) and overall survival (OS). Major cardiovascular adverse event incidence was estimated using the cumulative incidence function with non-cardiovascular death as a competing risk and compared by Gray\u2019s test, and PFS\/OS were analysed using Kaplan\u2013Meier methods with log-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 145 patients studied, CRS occurred in 120 patients (82%). Of those with CRS, 107 (89%) received tocilizumab within 24\u2005h. Within 1 year of therapy, 14 patients (9.7%) experienced MACE. Only patients with CRS developed MACE. The incidence of MACE was 8% [95% confidence interval (CI): 5%, 14%] at 6 months and 11% (95% CI: 7%, 19%) at 12 months. Progression-free survival at 12 months was 58% (95% CI: 50%, 68%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Progression-free survival and OS did not differ significantly based on incidence on CRS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjopen\/oeag097","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T11:39:15Z","timestamp":1780745955000},"source":"Crossref","is-referenced-by-count":0,"title":["Relationship between early use of tocilizumab during chimeric antigen receptor T-cell therapy for multiple myeloma and cardiovascular risk and progression-free survival"],"prefix":"10.1093","volume":"6","author":[{"given":"Sophia","family":"Golec","sequence":"first","affiliation":[{"name":"Tufts Medical Center , 800 Washington St, Boston, MA 02111 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Fu","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital , 1 Gustave Levy Pl, New York, NY 10029 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital , 1 Gustave Levy Pl, New York, NY 10029 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Peleg","sequence":"additional","affiliation":[{"name":"Jusidman Cancer Center, Institute of Oncology, Derech Sheba 2, Sheba Medical Center , Ramat Gan 52621 ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunna","family":"Pileggi","sequence":"additional","affiliation":[{"name":"Department of Cardio-Pneumonology, Heart Institute of the University of Sao Paulo , Av. Dr. En\u00e9as Carvalho de Aguiar, 44, Sao Paulo, Sao Paulo 05403 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[{"name":"Center of Excellence for Multiple Myeloma in the Tisch Cancer Institute at Mount Sinai Hospital , 1 Gustave Levy Pl, NewYork, NY 10029 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3503-6041","authenticated-orcid":false,"given":"Gagan","family":"Sahni","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital , 1 Gustave Levy Pl, New York, NY 10029 ,","place":["USA"]},{"name":"Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai , 1 Gustave Levy Pl, New York, NY 10029 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"2026062613422174200_oeag097-B1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2026062613422174200_oeag097-B2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2026062613422174200_oeag097-B3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2026062613422174200_oeag097-B4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"2026062613422174200_oeag097-B5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"2026062613422174200_oeag097-B6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2026062613422174200_oeag097-B7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026062613422174200_oeag097-B8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"2026062613422174200_oeag097-B9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2026062613422174200_oeag097-B10","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062613422174200_oeag097-B11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026062613422174200_oeag097-B12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","article-title":"Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies","volume":"13","author":"El-Cheikh","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026062613422174200_oeag097-B13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ejh.12677","article-title":"Real-life\u2019 experience of preapproval carfilzomib-based therapy in myeloma\u2014analysis of cardiac toxicity and predisposing factors","volume":"97","author":"Danhof","year":"2016","journal-title":"Eur J Haematol"},{"key":"2026062613422174200_oeag097-B14","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026062613422174200_oeag097-B15","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"2026062613422174200_oeag097-B16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2026062613422174200_oeag097-B17","doi-asserted-by":"crossref","first-page":"914959","DOI":"10.3389\/fimmu.2022.914959","article-title":"Timing of tocilizumab administration under the guidance of IL-6 in CAR-T therapy for R\/R acute lymphoblastic leukemia","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"2026062613422174200_oeag097-B18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaccao.2023.07.009","article-title":"Incidence of MACE in patients treated with CAR-T cell therapy: a prospective study","volume":"5","author":"Lefebvre","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026062613422174200_oeag097-B19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026062613422174200_oeag097-B20","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026062613422174200_oeag097-B21","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026062613422174200_oeag097-B22","doi-asserted-by":"crossref","first-page":"691064","DOI":"10.3389\/fonc.2021.691064","article-title":"An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: a single-centre retrospective study","volume":"11","author":"Qi","year":"2021","journal-title":"Front Oncol"},{"key":"2026062613422174200_oeag097-B23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001159","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026062613422174200_oeag097-B24","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026062613422174200_oeag097-B25","doi-asserted-by":"crossref","first-page":"477 e1","DOI":"10.1016\/j.jtct.2021.03.004","article-title":"Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma","volume":"27","author":"Banerjee","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2026062613422174200_oeag097-B26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-024-01048-0","article-title":"Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"14","author":"Costa","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026062613422174200_oeag097-B27","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1002\/hem3.132","article-title":"Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: implications for outpatient step-up dosing","volume":"8","author":"Korst","year":"2024","journal-title":"Hemasphere"},{"key":"2026062613422174200_oeag097-B28","doi-asserted-by":"crossref","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"key":"2026062613422174200_oeag097-B29","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jtct.2024.08.018","article-title":"Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2026062613422174200_oeag097-B30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2026062613422174200_oeag097-B31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp Hematol Oncol"}],"container-title":["European Heart Journal Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjopen\/advance-article-pdf\/doi\/10.1093\/ehjopen\/oeag097\/68493093\/oeag097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/6\/3\/oeag097\/68493093\/oeag097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/6\/3\/oeag097\/68493093\/oeag097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:42:30Z","timestamp":1782495750000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oeag097\/8704308"}},"subtitle":[],"editor":[{"given":"Magnus","family":"B\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjopen\/oeag097","relation":{},"ISSN":["2752-4191"],"issn-type":[{"value":"2752-4191","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"oeag097"}}